What is ARS Pharma?
Established in 2015 and headquartered in San Diego, California, ARS Pharma is a specialized pharmaceutical enterprise dedicated to transforming the treatment of severe allergic reactions. The company's core innovation lies in its intranasal epinephrine spray, which utilizes a unique absorption technology designed to provide a rapid, non-invasive alternative to traditional intramuscular injections. By focusing on high-stakes medical scenarios involving food, medication, and insect bite allergies, ARS Pharma addresses a critical unmet need in the emergency medicine market. The company's strategic focus on patient-centric delivery mechanisms positions it as a disruptive force in the allergy therapeutics space, aiming to improve patient outcomes through enhanced ease of use and efficacy.
How much funding has ARS Pharma raised?
ARS Pharma has raised a total of $75M across 2 funding rounds:
Series C
$20M
Series D
$55M
Series C (2018): $20M with participation from Deerfield
Series D (2021): $55M led by SR One, RA Capital Management, and Deerfield
Key Investors in ARS Pharma
Deerfield
Deerfield Management is an investment firm focused on advancing healthcare through investment, intelligence, and philanthropy. The firm supports companies across the healthcare ecosystem with flexible funding models and drives innovation using AI, data, and market research.
SR One
SR One is a prominent venture capital firm that specializes in supporting early-to-mid-stage biotechnology companies, focusing on transformative medical breakthroughs.
RA Capital Management
RA Capital Management is a multi-stage investment manager dedicated to evidence-based investing in public and private healthcare and life science companies.
What's next for ARS Pharma?
Looking ahead, the infusion of capital will likely be directed toward finalizing clinical trials and preparing for commercial launch activities. The company is expected to prioritize the scaling of its manufacturing capabilities to meet anticipated demand for its intranasal epinephrine product. Furthermore, the strategic backing from high-profile healthcare investors suggests a clear path toward market penetration and potential long-term value creation. As ARS Pharma continues to refine its regulatory strategy, the focus will remain on demonstrating the clinical superiority of its absorption technology, thereby securing its competitive advantage in the global allergy management market.
See full ARS Pharma company page
